KB-1100

RC108-hIgG1

12115

Home » RC108-hIgG1

Background of RC108-hIgG1

c-Met is a receptor tyrosine kinase that activates a variety of different cell signaling pathways, including those related to proliferation, motility, migration, and invasion, by binding to its ligand, hepatocyte growth factor. RC108-hIgG1 is a recombinant, fully humanized, monovalent monoclonal antibody that binds the extracellular domain of MET, blocking interaction with HGF. This prevents activation of the MET signaling pathway, inhibiting the downstream events that lead to tumorigenesis.

Specifications

Catalog Number	KB-1100
Antibody Name	RC108-hIgG1
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	MET
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659–23. doi: 10.1080/19420862.2016.1156829.
Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, et al. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res. 2017;23(4):992–1000.